IMB Dx, Inc. (KOSDAQ:461030)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,080.00
+600.00 (9.26%)
Apr 1, 2026, 3:30 PM KST
Market Cap99.25B -34.5%
Revenue (ttm)5.33B +10.0%
Net Income-7.93B
EPS-566.00
Shares Out14.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume72,006
Average Volume59,120
Open6,600.00
Previous Close6,480.00
Day's Range6,580.00 - 7,130.00
52-Week Range6,060.00 - 12,990.00
Betan/a
RSI49.11
Earnings Daten/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 461030
Full Company Profile

Financial Performance

In 2025, IMB Dx's revenue was 5.33 billion, an increase of 56.40% compared to the previous year's 3.41 billion. Losses were -7.93 billion, -17.15% less than in 2024.

Financial Statements